Khalid El Sayed advances natural product–derived leads for cancer control by combining bioassay‑guided isolation, HPLC‑based analytics, and mechanism‑driven pharmacology. Work centers on metabolism and epigenetic pathways to limit progression and recurrence in preclinical models.